
NM2CAB
NCAB

FIG. 1A


Zeta Potential (mV)
0
-20
-40
Poly-dispersity Index
0.4
0.3
0.2
0.1
Particle Diameter (nm)
400
350
300
250
10
20
30
40
50
60
70
80
90
100
Days

FIG. 1B


Drug uptake in MDM
CAB LAP
NMCAB
NM2CAB
nmol/10^6 cells
70
60
50
40
30
20
10
0
0
5
10
15
20
25
Hours
Drug retention in MDM
nmol/10^6 cells
60
50
40
30
20
10
0
0
5
10
15
20
25
30
Days

FIG. 2A


IC50
RT Activity (cpm/mL*10^4)
4
3
2
1
0
-3
-2
-1
0
1
2
3
Log(X)
X = Concentration (nM)
CAB LAP
NMCAB
NM2CAB
RT (%HIV-1 Control)
150
100
50
0
0
5
10
15
20
25
30
Days
HIV-1
CAB LAP
NMCAB
NM2CAB
Control

FIG. 2B



FIG. 2C


Plasma
100,000
10,000
1,000
100
10
1
CAB (ng/ml)
NCAB
NMCAB
NM2CAB
4x PA-IC90
PA-IC90
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360
Time (Days)

FIG. 3A


10000
1000
100
10
CAB (ng/mL)
NM3CAB
4×PA-IC90
PA-IC90
0
7
14
21
28
Day

FIG. 3B



FIG. 4


Spleen
Liver
Kidney
Gut
Lung
Blood
Brain
Rectal Tissue
LN-anatomical tissues
Prodrug (ng/g)
Prodrug (ng/mL)
Day
14
28
42
364
0
20
40
320
340
360
100000
10000
1000
100
10
1

FIG. 5


10000
1000
100
10
1
0.1
0.01
Drug (ng/ml)
PA-IC90
0
50
100
150
200
250
300
350
400
Day

FIG. 6A


100
10
1
CAB (ng/g)
1000
100
10
1
M2CAB (ng/g)
Rectal tissue
Lymph nodes
Adipose tissue

FIG. 6B